3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Vulvar Neoplasms
1
Uterine Cervical Neoplasms
1
Rectal Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Melanoma
1
Head and Neck Neoplasms
1
Endometrial Neoplasms
1
Carcinoma, Squamous Cell
1
Breast Neoplasms
1
Anus Neoplasms
1
Interventions
Paclitaxel
25
Doxorubicin
15
Carboplatin
14
pembrolizumab
10
Cisplatin
8
Radiotherapy
6
Docetaxel
5
Chemotherapy, Adjuvant
5
Taxes
4
Filgrastim
4
Brachytherapy
4
lenvatinib
3
Observation
3
trastuzumab deruxtecan
2
selinexor
2
olaparib
2
durvalumab
2
Tamoxifen
2
Specimen Handling
2
Ifosfamide
2
Drug Therapy
2
sintilimab
1
sacituzumab govitecan
1
pertuzumab
1
nanocis
1
liposomal doxorubicin
1
ixabepilone
1
gallium-diethylenetriaminepentaacetic acid-mannosyl-dextran
1
dostarlimab
1
atezolizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Endometrial Neoplasms
×
nanocis
×
Clear all
NCT02997553
2023-01-09
GASVERT
Institut de Cancérologie de Lorraine
Phase 3
Completed
744 enrolled